When considering the CID subgroups except for Crohn ́s disease, being in a High MFAP4 (having a high serum MFAP4 level) predicts a positive treatment response to biologic therapy; however, the subgroups were underpowered for individual analysis, resulting in wide CI’s. This evidence concerns the gene MFAP4 and Crohn disease.